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the Decision Resources Group’s ‘Global Market Access Solution’ database were 
reviewed. Results: The healthcare systems in Brazil, Argentina and Mexico are 
decentralised, while that of Colombia is centrally managed. All countries have a 
national health service for all residents, but the proportion of the population that 
relies solely on this varies greatly between countries. In Brazil, 25% of the popula-
tion has private health insurance, while only a small proportion of the popula-
tion relies on private insurance in the other countries. In Mexico and Argentina, 
residents in formal employment are obliged to enrol in one of the social security 
sponsored schemes. In Brazil, Argentina and Colombia, national formularies include 
the mandatory minimum healthcare provision. In Mexico, the national formulary 
is not binding and the different social security schemes decide which treatments 
to cover. The role of health technology assessment (HTA) in the reimbursement 
process varies in different countries. In Brazil, Mexico and Colombia, HTA is criti-
cal in the reimbursement decision process, while in Argentina it has been mostly 
used to assess treatments for catastrophic illnesses; although there is a drive to 
include HTA in the decision process. Opportunities include a growing demand for 
pharmaceuticals, and challenges include decentralised healthcare systems and high 
use of generics. ConClusions: Most countries have a decentralised system where 
reimbursement decision making occurs at the regional level or at the social security 
funds level. HTA is critical in decision making in Brazil, Mexico and Colombia, but 
not yet in Argentina. We have identified current opportunities and challenges for 
the different countries.
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BACkgRound: Evidence bases medicine is the governing principle ruling all aspects 
of a new medical product. Marketing authorization organizations and health tech-
nology agencies focused on the reimbursement aspects of a new product are both 
relying in their decision making process on clinical data of the highest possible 
evidence. While marketing authorization is an increasingly international process 
with standardized rules, the reimbursement process is conducted on a national 
level with country-specific requirements. In some indications, e.g. in chronic dis-
eases, where it is difficult to recruit newly diagnosed patients for clinical trials, 
establishing the efficacy of a product against placebo is a common approach, as 
only patients who did not succeed with the available treatment options are willing 
to participate in these trials. oBjeCtives: To review the national requirements for 
the reimbursement of new medical products with a positive centralized marketing 
authorization based on placebo-controlled clinical trials. We will demonstrate that 
the acceptance of placebo-controlled trials is handled differently between coun-
tries and that different strategies to process these data are necessary. Methods: 
We focused on the national health technology agencies of five representative 
European countries, including the United Kingdom, France, Germany, Sweden and 
the Netherlands. A targeted desktop research on the published methodology and 
the decisions regarding medical products with a marketing authorization based 
on placebo controlled trials for the most recent years was conducted. Results: 
The methodological requirements to get reimbursement for a medical product 
with a marketing authorization based on placebo-controlled trials are different 
in these countries, leading to heterogeneous decisions. ConClusions: Getting a 
positive decision for reimbursement is challenging for products which have mar-
keting authorization based on placebo-controlled trials. The national requirements 
and thresholds for reimbursement are very different and highly dependent on the 
governing principle for evaluation, ranging from quality of life based decisions to 
comparator driven additional benefit decisions.
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oBjeCtives: Resolutions on early benefit assessment can be granted with a time 
restriction, termed “limited”. As a consequence companies are required to resubmit 
their data later. The objective of the present study was to assess reasons for limita-
tion. Methods: The following three criteria are given for limiting a resolution: 
incomplete data on patient relevant endpoints, limited quality of evidence, and 
missing data can be provided at a later stage. Assessment was based on resolutions 
with limitations published until June 2016. For each resolution reasons for limita-
tions were identified and requirements for a resubmission were captured using 
supporting documents (“Tragende Gruende”). Results: 26 out of 130 resolutions 
(20%) were limited with limitations ranging from 1 to 5 years. In 18 resolutions (69%) 
G-BA made reference to missing data on endpoints. In further 18 resolutions the 
G-BA explicitly referred to limited quality of evidence. Expectations for better data 
in the future are mentioned in 13 resolutions (50%). More information on what data 
is required for a reassessment is provided in 8 resolutions (31%). ConClusions: 
Most limitations are made even though they do not meet (all) legal criteria. Missing 
information on the requirements for reassessment increases the risk for subse-
quent failure.
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oBjeCtives: The use of innovative medicines has been associated with increased 
healthcare-related expenditure in the EU5 (Italy, France, Spain, UK and Germany). 
In some countries, this has raised concerns over the clinical and economic assess-
ment of such medicines and has led to the introduction of additional criteria to 
orphan drugs assessments between January 2011 and May 2015 and compari-
son with assessments conducted by HTA agencies in France, Netherlands, the 
UK and Canada, to examine similarities and differences in benefit evaluations, 
reimbursement and drug access. Results: Germany has 23 completed assess-
ments for 21 orphan drugs during the time frame. 9 received non quantifiable 
additional benefit, 11 marginal and 3 significant. Out of 5 drugs where different 
patient subgroups were identified, only 1 (ivacaftor) received different ratings 
across two patient subgroups (marginal and significant). This 21 orphan drug 
sub-set was then compared across the other countries. In France, 19 (90.5%) were 
recommended for reimbursement. Comparing the additional benefit ratings 
assigned in Germany with the French ASMR ratings, we found significantly dif-
ferent value assessments for 15 (78.9%) out of 19 drugs reviewed in both countries. 
In the Netherlands, HTA’s by the National Health Care Institute were available for 
7 (33.3%) drugs: 5 (23.8%) were reimbursed, all with restrictions. SMC reviewed 14 
(66.7%) drugs of which 5 (23.8%) were not recommended (3: non-submission and 2: 
economic considerations). Of the 9 (42.9%) drugs that were recommended, 6 had a 
negotiated patient access scheme (PAS). NICE reviewed 5 (23.8%) drugs, 4 of which 
were for oncology and not recommended for reimbursement. Only one (4.8%) 
drug (pirfenidone) was recommended for restricted use based on a PAS. Canada’s 
CADHT assessed 6 (28.6%) drugs: only 4 (19.0%) were listed with restrictions after 
price reductions. ConClusions: Among the countries examined, Germany had 
the highest number of orphan drugs assessed. Differences in HTA assessment 
criteria lead to noticeably different benefit evaluations, recommendations and, 
ultimately, drug access.
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oBjeCtives: The primary focus of manufacturers’ reimbursement submissions in 
Germany is on demonstrating the added benefit of a product versus the appropri-
ate comparator(s). Some decisions made by Gemeinsamer Bundesausschuss (G-BA) 
result in a time-limited approval, after which there should be a review. This study 
analyses any completed reviews conducted by the G-BA. Methods: G-BA deci-
sions were searched to identify restricted decisions and subsequent reviews. Data 
were extracted, the reasons for the restrictions and the ways these were addressed 
in the reviews, were analysed. Results: 20% (27/135) of all decisions identified 
were time restricted. Restrictions were mainly applied to products with small or 
no added benefit. The most common reason for a restriction was incomplete evi-
dence profiles, and the most common restriction period was three years. Of the 27 
restrictions identified, two reviews have taken place, two restriction periods have 
been extended and five more decisions are expected by the end of 2015. An analysis 
of the completed eribulin review showed that the manufacturer was granted suf-
ficient time to collect additional evidence and that the G-BA adjusted its recom-
mendations in a favourable manner once further evidence was provided. However, 
during the vemurafenib review the level of added benefit did not change from the 
original evaluation. This indicates the manufacturer did not present sufficient data 
to address the original criticism and was therefore unable to raise the level of added 
benefit. Furthermore, it is evident that the G-BA takes regulatory guidance into con-
sideration in decision making. ConClusions: The results indicate that restricted 
decisions provide manufacturers with the opportunity to collect additional data 
and improve the final added benefit recommendation. If manufacturers address 
the G-BA’s criticism of the original submission, more favourable added benefit levels 
can be achieved during the review. Furthermore, it shows that EMA decisions influ-
ence G-BA decision making.
PHP213
assessing PHarmaCeutiCals witH limited evidenCe in germany – 
Current exPerienCe
Ecker T, Fink C, Puetz C
Ecker + Ecker GmbH, Hamburg, Germany
oBjeCtives: Benefit assessment usually requires RCT data. Orphan drugs are 
granted additional benefit by law, but not drugs with conditional or exceptional 
approval or PUMA. The objective of this study was to assess how their status is 
handled in benefit assessment. Methods: All resolutions until June 2016 were 
analyzed whether they have been approved by EMA under these circumstances. 
Those which do were assessed regarding underlying evidence, extend of additional 
benefit and other aspects of the resolution. Results: 7 out of 104 resolutions (7%) 
met these criteria – 5 with conditional approval, 1 with exceptional circumstances 
and 1 PUMA. 2 out of 7 products had only non-RCT evidence. For 6 products the 
IQWiG found no additional benefit and for 1 product a major additional benefit. The 
G-BA increased three products to minor (or considerable) additional benefit, even 
though one approval was based only on a case series. However, for three products 
the result was still “additional benefit not proven”. 4 out of 7 resolutions had been 
limited. ConClusions: Special regulatory status gives no formal advantage in 
benefit assessment. However G-BA seems to take their status into account and 
using limitations to account for future evidence.
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oBjeCtives: To define the current processes and key decision makers involved 
in gaining market access in Brazil, Argentina, Mexico and Colombia, and identify 
opportunities and challenges to market access in these countries. Methods: 
The websites of the appropriate authorities and agencies in each country and 
